Targeting myeloid leukemia stem cells

Science Translational Medicine

Volumn 2, Issue 31, 2010, Pages

  Jordan, Craig T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C TYPE LECTIN LIKE MOLECULE 1; CD123 ANTIGEN; CD32 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD47 ANTIGEN; CD96 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; LECTIN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; CANCER STEM CELL; HUMAN; IMMUNOPHENOTYPING; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SHORT SURVEY; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID; NEOPLASTIC STEM CELLS;

EID: 77953005040     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000914     Document Type: Short Survey

References (26)

1. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M. A. Caligiuri, J. E. Dick, A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
2. D. Bonnet, J. E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997).
3. T. Reya, S. J. Morrison, M. F. Clarke, I. L. Weissman, Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
4. T. Pearson, D. L. Greiner, L. D. Shultz, Humanized SCID mouse models for biomedical research. Curr. Top. Microbiol. Immunol. 324, 25-51 (2008).
5. A. Blair, D. E. Hogge, L. E. Ailles, P. M. Lansdorp, H. J. Sutherland, Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89, 3104-3112 (1997).
6. A. Blair, H. J. Sutherland, Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp. Hematol. 28, 660-671 (2000).
7. A. Blair, D. E. Hogge, H. J. Sutherland, Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. Blood 92, 4325-4335 (1998).
8. C. T. Jordan, D. Upchurch, S. J. Szilvassy, M. L. Guzman, D. S. Howard, A. L. Pettigrew, T. Meyerrose, R. Rossi, B. Grimes, D. A. Rizzieri, S. M. Luger, G. L. Phillips, The interleukin- 3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14, 1777-1784 (2000).
9. A. van Rhenen, B. Moshaver, A. Kelder, N. Feller, A. W. Nieuwint, S. Zweegman, G. J. Ossenkoppele, G. J. Schuurhuis, Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21, 1700-1707 (2007).
10. L. Jin, E. M. Lee, H. S. Ramshaw, S. J. Busfield, A. G. Peoppl, L. Wilkinson, M. A. Guthridge, D. Thomas, E. F. Barry, A. Boyd, D. P. Gearing, G. Vairo, A. F. Lopez, J. E. Dick, R. B. Lock, Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5, 31-42 (2009).
11. A. van Rhenen, G. A. van Dongen, A. Kelder, E. J. Rombouts, N. Feller, B. Moshaver, M. Stigter-van Walsum, S. Zweegman, G. J. Ossenkoppele, G. Jan Schuurhuis, The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110, 2659-2666 (2007).
12. A. van Rhenen, N. Feller, A. Kelder, A. H. Westra, E. Rombouts, S. Zweegman, M. A. van der Pol, Q. Waisfisz, G. J. Ossenkoppele, G. J. Schuurhuis, High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520-6527 (2005).
13. D. J. Pearce, D. C. Taussig, D. Bonnet, Implications of the expression of myeloid markers on normal and leukemic stem cells. Cell Cycle 5, 271-273 (2006).
14. D. C. Taussig, D. J. Pearce, C. Simpson, A. Z. Rohatiner, T. A. Lister, G. Kelly, J. L. Luongo, G. A. Danet-Desnoyers, D. Bonnet, Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106, 4086- 4092 (2005).
15. P. R. Hamann, L. M. Hinman, I. Hollander, C. F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H. R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D. A. Flowers, I. Bernstein, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13, 47-58 (2002).
16. R. A. Larson, E. L. Sievers, E. A. Stadtmauer, B. Löwenberg, E. H. Estey, H. Dombret, M. Theobald, D. Voliotis, J. M. Bennett, M. Richie, L. H. Leopold, M. S. Berger, M. L. Sherman, M. R. Loken, J. J. van Dongen, I. D. Bernstein, F. R. Appelbaum, Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104, 1442-1452 (2005).
17. L. Jin, K. J. Hope, Q. Zhai, F. Smadja-Joffe, J. E. Dick, Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174 (2006). (Pubitemid 44527352)
18. D. S. Krause, K. Lazarides, U. H. von Andrian, R. A. Van Etten, Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat. Med. 12, 1175-1180 (2006).
19. R. S. Charrad, Y. Li, B. Delpech, N. Balitrand, D. Clay, C. Jasmin, C. Chomienne, F. Smadja-Joffe, Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat. Med. 5, 669-676 (1999).
20. R. Majeti, M. P. Chao, A. A. Alizadeh, W. W. Pang, S. Jaiswal, K. D. Gibbs Jr., N. van Rooijen, I. L. Weissman, CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
21. S. Jaiswal, C. H. Jamieson, W. W. Pang, C. Y. Park, M. P. Chao, R. Majeti, D. Traver, N. van Rooijen, I. L. Weissman, CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271-285 (2009).
22. N. Hosen, C. Y. Park, N. Tatsumi, Y. Oji, H. Sugiyama, M. Gramatzki, A. M. Krensky, I. L. Weissman, CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 104, 11008-11013 (2007).
23. Y. Saito, H. Kitamura, A. Hijikata, M. Tomizawa-Murasawa, S. Tanaka, S. Takagi, N. Uchida, N Suzuki, A. Sone, Y. Najima, H. Ozawa, A. Wake, S. Taniguchi, L. D. Shultz, O. Ohara, F. Ishikawa, Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci. Transl. Med. 2, 17ra19 (2010).
24. D. C. Taussig, F. Miraki-Moud, F. Anjos-Afonso, D. J. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S. G. Agrawal, T. A. Lister, J. G. Gribben, D. Bonnet, Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemiainitiating cells. Blood 112, 568-575 (2008).
25. D. C. Taussig, J. Vargaftig, F. Miraki-Moud, E. Griessinger, K. Sharrock, T. Luke, D. Lillington, H. Oakervee, J. Cavenagh, S. G. Agrawal, T. A. Lister, J. G. Gribben, D. Bonnet, Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115, 1976-1984 (2010).
26. J.-E. Sarry, K. Murphy, G. Danet-Desnoyers, M. Carroll, Acute myeloid leukemia stem cells are rare and heterogeneous in human acute myeloid leukemia. Blood 114, 390 (2009) (ASH Annual Meeting Abstracts, http://abstracts. hematologylibrary.org/cgi/content/abstract/114/22/390).